利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.024 秒)

    Method of treating tumors using O-substituted fumagillol derivatives
    3.
    发明授权
    Method of treating tumors using O-substituted fumagillol derivatives 失效
    使用O-取代的烟曲霉醇衍生物治疗肿瘤的方法

    公开(公告)号：US6017954A

    公开(公告)日：2000-01-25

    申请号：US940123

    申请日：1992-09-03

    申请人： Moses J. Folkman ,  Donald Ingber ,  Takeshi Fujita

    发明人： Moses J. Folkman ,  Donald Ingber ,  Takeshi Fujita

    IPC分类号： A61K31/335 ,  A61K31/336 ,  C07D303/22 ,  C07D405/14 ,  C07D407/14 ,  C07D417/14 ,  C07D521/00 ,  A01N43/20

    CPC分类号： C07D303/22 ,  A61K31/335 ,  A61K31/336 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D405/14 ,  C07D407/14 ,  C07D417/14

    摘要： This invention relates to methods of using O-substituted fumagillol derivatives or salts thereof preferably, O-(N-chloroacetylcarbamoyl) fumagillol, O-(N-chloroacetylcarbamoyl)dihydrofumagillol or O-(N-chloracetylcarbamoyl)-6'b-hydroxyfumagillol, which have angiogenesis inhibitory activity, in the treatment and prevention of various diseases caused or advanced by abnormally hyperactive angiogenesis, especially various inflammatory diseases (rheumatism, psoriasis, etc.), diabetic retinopathy and cancer and other angiogenesis-dependent tumors, especially Kaposi's sarcoma, breast cancer, colon cancer.

    摘要翻译： 本发明涉及使用O-取代的烟曲霉醇衍生物或其盐优选O-（N-氯乙酰基氨基甲酰基）烟曲霉醇，O-（N-氯乙酰基氨基甲酰基）二氢烟曲霉素或O-（N-氯乙酰基氨基甲酰基）-6'-羟基烟曲霉素的方法，其中 具有血管生成抑制活性，用于治疗和预防由异常血液生成异常引起或促进的各种疾病，特别是各种炎性疾病（风湿病，牛皮癣等），糖尿病性视网膜病变和癌症以及其它血管生成依赖性肿瘤，特别是卡波西肉瘤，乳腺癌 癌症，结肠癌。

    Porous biodegradable polymeric materials for cell transplantation
    5.
    发明申请
    Porous biodegradable polymeric materials for cell transplantation 失效

    公开(公告)号：US20060141000A1

    公开(公告)日：2006-06-29

    申请号：US10775768

    申请日：2004-02-10

    申请人： Antonios Mikos ,  Donald Ingber ,  Joseph Vacanti ,  Robert Langer

    发明人： Antonios Mikos ,  Donald Ingber ,  Joseph Vacanti ,  Robert Langer

    IPC分类号： A61K35/12

    CPC分类号： G02B27/0031 ,  A61L27/18 ,  A61L27/56 ,  A61L2400/06 ,  G03F7/40 ,  H01L21/0273 ,  H01L21/32139 ,  C08L67/04

    摘要： Polymeric materials are used to make a pliable, non-toxic, injectable porous template for vascular ingrowth. The pore size, usually between approximately 100 and 300 microns, allows vascular and connective tissue ingrowth throughout approximately 10 to 90% of the matrix following implantation, and the injection of cells uniformly throughout the implanted matrix without damage to the cells or patient. The introduced cells attach to the connective tissue within the matrix and are fed by the blood vessels. The preferred material for forming the matrix or support structure is a biocompatible synthetic polymer which degrades in a controlled manner by hydrolysis into harmless metabolites, for example, polyglycolic acid, polylactic acid, polyorthoester, polyanhydride, or copolymers thereof. The rate of tissue ingrowth increases as the porosity and/or the pore size of the implanted devices increases. The time required for the tissue to fill the device depends on the polymer crystallinity and is less for amorphous polymers versus semicrystalline polymers. The vascularity of the advancing tissue is consistent with time and independent of the biomaterial composition and morphology.

    Method and apparatus for displaying information
    8.
    发明申请
    Method and apparatus for displaying information 审中-公开

    公开(公告)号：US20060098011A1

    公开(公告)日：2006-05-11

    申请号：US11108623

    申请日：2005-04-18

    申请人： Donald Ingber ,  Sui Huang ,  Gabriel Eichler

    发明人： Donald Ingber ,  Sui Huang ,  Gabriel Eichler

    IPC分类号： G06T11/20

    CPC分类号： G06T11/60

    摘要： A method for displaying large amounts of information. The method includes the steps of forming a spatial layout of tiles each corresponding to a representative reference element; mapping observed elements onto the spatial layout of tiles of representative reference elements; assigning a respective value to each respective tile of the spatial layout of the representative elements; and displaying an image of the spatial layout of tiles of representative elements. Each tile includes atomic attributes of representative elements. The invention also relates to an apparatus for displaying large amounts of information. The apparatus includes a tiler forming a spatial layout of tiles, each corresponding to a representative reference element; a comparator mapping observed elements onto said spatial layout of tiles of representative reference elements; an assigner assigning a respective value to each respective tile of said spatial layout of representative reference elements; and a display displaying an image of the spatial layout of tiles of representative reference elements.

    Angiostatic collagen modulators
    9.
    发明授权
    Angiostatic collagen modulators 失效
    血管内胶原调节剂

    公开(公告)号：US5021404A

    公开(公告)日：1991-06-04

    申请号：US183973

    申请日：1988-04-20

    申请人： Judah Folkman ,  Donald Ingber

    发明人： Judah Folkman ,  Donald Ingber

    IPC分类号： A61K45/06 ,  A61K31/57 ,  A61P9/00 ,  A61P27/02 ,  A61P43/00

    CPC分类号： A61K31/715 ,  A61K31/57 ,  Y10S514/964

    摘要： Angiostatic compounds are potentiated by collagen matrix metabolism modulators including:a) proline analogs which inhibit proline hydroxylation when substituted for proline in collagen;b) inhibitors of proline hydroxylase;c) inhibitors of collagen cross-linking; andd) all trans-retinoic acid.In methods and therapeutic compositions for inhibiting angiogenesis in a mammal, the collagen matrix modulator is administered with an angiostatic steroid or with heparin (including angiostatic heparin fragments of six or more sugar units, and synthetic fragments).

    摘要翻译： 胶原蛋白基质代谢调节剂增强血管抑制作用，包括：a）当胶原中取代脯氨酸时抑制脯氨酸羟基化的脯氨酸类似物; b）脯氨酸羟化酶抑制剂; c）胶原交联抑制剂; 和d）全反式视黄酸。 在用于抑制哺乳动物血管发生的方法和治疗组合物中，胶原基质调节剂与血管抑制类固醇或肝素（包括6个或更多个糖单位的血管抑制性肝素片段和合成片段）一起给药。